Lusedra

Lusedra is a brand name of fospropofol, approved by the FDA in the following formulation(s):

LUSEDRA (fospropofol disodium - solution; intravenous)

• 
  Manufacturer: EISAI INC
  
  Approval date: December 12, 2008
  
  Strength(s): 1050MG/30ML (35MG/ML) ^[RLD]

Has a generic version of Lusedra been approved?

No. There is currently no therapeutically equivalent version of Lusedra available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lusedra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Water soluble prodrugs of hindered alcohols
  Patent 6,204,257
  Issued: March 20, 2001
  Inventor(s): Stella; Valentino J. & Zygmunt; Jan J. & Georg; Ingrid Gunda & Safadi; Muhammad S.
  Assignee(s): Universtiy of Kansas
  The present invention is directed to novel water-soluble prodrugs of aliphatic or aromatic hindered hydroxyl group containing pharmaceuticals.
  
  Patent expiration dates:
  
  
  • August 7, 2018
    
    ✓ 
    Patent use: SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Water soluble prodrugs of hindered alcohols
  Patent 6,872,838
  Issued: March 29, 2005
  Inventor(s): Stella; Valentino J. & Zygmunt; Jan J. & Georg; Ingrid Gunda & Safadi; Muhammad S.
  Assignee(s): University of Kansas
  The present invention is directed to novel water-soluble prodrugs of aliphatic or aromatic hindered hydroxyl group containing pharmaceuticals.
  
  Patent expiration dates:
  
  
  • August 7, 2018
    
    ✓ 
    Drug substance
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 12, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Lusedra Consumer Information (Drugs.com)
• Lusedra Advanced Consumer Information (Micromedex)
• Lusedra AHFS DI Monographs (ASHP)
• Fospropofol Intravenous Advanced Consumer Information (Micromedex)
• Fospropofol AHFS DI Monographs (ASHP)